Company Description
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate.
Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Matthew Angel |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States | |
| Phone | 415 798 8589 |
| Website | tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1544227 |
| CUSIP Number | 87978U207 |
| ISIN Number | US87978U2078 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 8-K | Current Report |
| Oct 26, 2026 | DEF 14A | Other definitive proxy statements |
| Oct 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 16, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 14, 2026 | D | Notice of Exempt Offering of Securities |
| Oct 2, 2026 | 424B3 | Prospectus |
| Oct 1, 2026 | EFFECT | Notice of Effectiveness |
| Sep 28, 2026 | 8-K | Current Report |